Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold"

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.

HURA has been the topic of several other research reports. Brookline Capital Management upgraded TuHURA Biosciences to a "strong-buy" rating in a research note on Monday, June 23rd. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $12.67.

TuHURA Biosciences Trading Up 4.1%

Shares of NASDAQ:HURA traded up $0.11 during midday trading on Friday, reaching $2.66. 168,440 shares of the company were exchanged, compared to its average volume of 262,586. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93. The stock has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $3.44.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. acquired a new position in TuHURA Biosciences in the 4th quarter valued at $61,000. Accent Capital Management LLC acquired a new position in TuHURA Biosciences in the 4th quarter valued at $29,000. Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $1,084,000. Hurlow Wealth Management Group Inc. bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $170,000. Finally, TT Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $41,000. 0.62% of the stock is owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.